4 studies found for:    16083709 [PUBMED-IDS]
Show Display Options
Rank Status Study
1 Terminated EXtended Therapy in Hepatitis C Genotype 3 Infected Patients
Condition: Chronic Hepatitis C
Intervention: Drug: Peginterferon alfa-2b (Pegetron) plus ribavirin (Rebetol)
2 Unknown  Four Arms, Multicenter Study of Tailored Regimens With Peginterferon Plus Ribavirin for Genotype 2 Chronic Hepatitis C
Condition: Chronic Hepatitis C
Interventions: Drug: pegylated interferon alpha 2a and plus ribavirin;   Drug: Pegylated interferon alfa-2a and ribavirin;   Drug: pegylated interferon alpha 2a and ribavirin
3 Terminated Study to Assess the Efficacy of 12 Versus 24 Weeks of Extended Treatment in HCV-Genotype 2/3 Patients
Condition: Hepatitis C, Chronic
Interventions: Drug: pegylated interferon alpha-2b;   Drug: Ribavirin;   Drug: pegylated Interferon alpha-2b
4 Completed Peginterferon Alfa-2a and Ribavirin for Genotype 2 Chronic Hepatitis C: Duration and Ribavirin Dose Stratified by RVR
Condition: Chronic Hepatitis C
Interventions: Drug: Peg-IFN + WB RBV for 16 weeks;   Drug: Peg-IFN + LD RBV for 16 weeks;   Drug: Peg-IFN + WB RBV for 24 weeks;   Drug: Peg-IFN + WB RBV for 48 weeks;   Drug: Peg-IFN + LD RBV for 24 weeks

Indicates status has not been verified in more than two years